Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Cyclosporine Market Grown from 2024 to 2025?

In the past few years, we’ve seen a fast-paced expansion in the cyclosporine market. It is projected to increase from $2.65 billion in 2024 to $3.01 billion in 2025, with a compound annual growth rate (CAGR) of 13.5%. Factors contributing to the growth in the historical period encompass an upsurge in organ transplant rates, a rise in autoimmune disorders, an increase in chronic illnesses, a peak in kidney disease occurrences, and the broadening of transplant centers.

What Growth Rate Is Anticipated for the Cyclosporine Market in the Coming Years?

Anticipations highlight rapid expansion in the cyclosporine market over the next few years, reaching a value of $4.96 billion in 2029 with a compound annual growth rate (CAGR) of 13.3%. This surge during the forecasted period can be credited to factors such as an increase in organ donations, wider use of immunotherapy, a growing number of elderly patients, the expansion of the specialty pharmaceutical market, and the increasing occurrences of rheumatoid arthritis. Significant trends in the forecast period encompass the emergence of innovative immunosuppressive treatments, advancements in AI-enabled drug development, progress in nanotechnology incorporation, breakthroughs in integrating blockchain in the drug supply chain, and improvements in drug delivery.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23360&type=smp

Who Are the Leading Companies in the Cyclosporine Market?

Major companies operating in the cyclosporine market are Novartis AG, Viatris Inc., Teva Pharmaceutical Industries Ltd, Sandoz International GmbH, Sun Pharmaceutical Industries Ltd, Apotex Inc., Cipla Ltd, Dr. Reddy’s Laboratories Ltd, Lupin Limited, Glenmark Pharmaceuticals Ltd, Taj Pharmaceuticals Limited, Panacea Biotec Ltd, Novaliq GmbH, Simson Pharma Limited, Strides Pharma Science Ltd, AdvaCare Pharma, JoinHub Pharma, Grevis Pharmaceuticals Pvt Ltd, GMT Pharma International, Logos Pharma.

What Are the Key Drivers of the Cyclosporine Market?

The cyclosporine market is projected to expand due to the increasing incidence of autoimmune diseases. These diseases, which occur when the immune system erroneously targets the body’s cells, resulting in inflammation, tissue destruction, and longstanding diseases, are becoming more common. In large part, this is as a result of a genetic predisposition to these conditions, which has been identified in more people through advancements in genetic testing, making them more prone to these diseases. Cyclosporine, which suppresses T-cell activation, effectively mitigates the detrimental immune reactions towards healthy tissues in conditions like rheumatoid arthritis, psoriasis, and lupus. Specifically, a report from May 2024 published by the National Institutes of Health (NIH), a US government department, revealed a prevalence of psoriatic arthritis (PsA) of 0.221% and an incidence rate of 13.54 per 100,000 people in 2022. Thus, the increasing prevalence of autoimmune diseases is fuelling the growth of the cyclosporine market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=23360&type=smp

What Are the Key Market Segments in the Cyclosporine Industry?

The cyclosporine market covered in this report is segmented –

1) By Indication: Transplant Rejection Prophylaxis, Rheumatoid Arthritis, Psoriasis, Autoimmune Myasthenia Gravis, Dry Eye, Other Indications

2) By Dosage Form: Capsule, Eye Drops, Liquid Solutions, Creams And Ointments

3) By Route Of Administration: Oral, Topical, Parenteral

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-Users: Hospitals, Homecare, Speciality Centres, Other End-Users

Subsegments:

1) By Transplant Rejection Prophylaxis: Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant, Other Transplants

2) By Rheumatoid Arthritis: Moderate Rheumatoid Arthritis, Severe Rheumatoid Arthritis

3) By Psoriasis: Plaque Psoriasis, Erythrodermic Psoriasis, Guttate Psoriasis, Pustular Psoriasis

4) By Autoimmune Myasthenia Gravis: Generalized Myasthenia Gravis, Ocular Myasthenia Gravis

5) By Dry Eye: Chronic Dry Eye, Severe Dry Eye

6) By Other Indications: Atopic Dermatitis, Uveitis, Nephrotic Syndrome, Inflammatory Bowel Disease (IBD)

What Are the Latest Trends in the Cyclosporine Market?

Primary players in the cyclosporine market are intent on obtaining regulatory clearances to broaden their product range and strengthen their market position. Obtaining endorsements for cyclosporine validates its safety and effectiveness, facilitates market penetration, and boosts trust among prescribers and patients. To illustrate, Novaliq GmbH, a biopharmaceutical organization based in Germany, gained U.S. FDA approval in June 2023 for VEVYE (cyclosporine ophthalmic solution) 0.1%, a unique, preservative-free ophthalmic medicine developed explicitly for dry eye disease (DED) treatment. This is the first-ever cyclosporine-based solution for this ailment, demonstrating effectiveness in as short as four weeks. VEVYE utilizes an advanced water-free technology called EyeSol, enhancing cyclosporine’s bioavailability and duration of stay on the eye surface without the necessity for preservatives, oils, or surfactants. The solution acts as a calcineurin suppressor, aiding in the reduction of inflammation associated with dry eye disease.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/cyclosporine-global-market-report

What Are the Key Regional Markets in the Cyclosporine Industry?

Asia-Pacific was the largest region in the cyclosporine market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the cyclosporine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23360

This Report Delivers Insight On:

1. How big is the cyclosporine market, and how is it changing globally?

2. Who are the major companies in the cyclosporine market, and how are they performing?

3. What are the key opportunities and risks in the cyclosporine market right now?

4. Which products or customer segments are growing the most in the cyclosporine market?

5. What factors are helping or slowing down the growth of the cyclosporine market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model